Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i> effects on extracellular flux via glycolysis and mitochondrial stress tests suggest that candidate compounds 3 and 9 disrupt glycolysis and OxPhos efficiently in MCT1 expressing colorectal adenocarcinoma WiDr and MCT4 expressing triple negative breast cancer MDA-MB-231 cells.
|
31040927 |
2019 |
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
|
17483329 |
2007 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
MCT4 protein expression was upregulated (P < 0.0001) in ccRCC and showed significant association with cancer-related death.
|
23881922 |
2013 |
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
|
25497091 |
2014 |
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.
|
25497091 |
2014 |
Malignant neoplasm of stomach stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis.
|
27224918 |
2016 |
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MCT-4, directly mediated by HIF-1α, maintains a high level of glycolysis, and the enhanced glycolysis promotes pro-inflammatory properties, which are involved in arsenite carcinogenesis.
|
28419250 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter 4 (MCT-4) serves a key function in transporting lactate across the plasma membrane in various types of human cancer.
|
29113201 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter 4 (MCT-4) serves a key function in transporting lactate across the plasma membrane in various types of human cancer.
|
29113201 |
2017 |
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
MCT-4 protein expression was significantly associated with depth of invasion (P=0.034).
|
29113201 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MCT4 is a marker of tumor-associated stroma in neoplastic tissue.
|
29248132 |
2017 |
Carcinomatosis of peritoneal cavity
|
0.020 |
Biomarker
|
disease |
BEFREE |
MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis.
|
29483215 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter-4 (MCT4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies.
|
30051648 |
2018 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Monocarboxylate Transporter 4 (MCT4) Knockout Mice Have Attenuated 4NQO Induced Carcinogenesis; A Role for MCT4 in Driving Oral Squamous Cell Cancer.
|
30211114 |
2018 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Monocarboxylate transporter 4 (MCT4) is a membrane transporter of monocarboxylates that has been reported to play an important role in tumorigenesis and progression in several solid tumor types.
|
30226548 |
2018 |
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line.
|
31217781 |
2019 |
Hamartoma Syndrome, Multiple
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCT4 upregulation was critical for fibroblast viability under CS conditions.
|
31239287 |
2019 |
Cortical cataract
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCT4 upregulation was critical for fibroblast viability under CS conditions.
|
31239287 |
2019 |
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Monocarboxylate transporter 4 (MCT4) is an H<sup>+</sup>-coupled symporter highly expressed in metastatic tumors and at inflammatory sites undergoing hypoxia or the Warburg effect.
|
31719150 |
2019 |
NONAKA MYOPATHY
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A 24 hours treatment with 1,25(OH)2D3 (100 nM) significantly increased cytosolic pH (pHi), significantly decreased Na+/H+ exchanger activity, NHE1 and MCT4 transcript levels as well as protein abundance and significantly increased lactate concentration in the supernatant.
|
28222424 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A survival curve analysis indicated that high MCT-4 expression in lung AC was associated with a decreased overall survival rate (P=0.001).
|
29113201 |
2017 |
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
A tissue microarray of various Gleason grade human prostate cancers was stained for MCT4 protein.
|
26755530 |
2016 |
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 15 targeted studies and 16 untargeted studies revealed several potential metabolite signatures of TC such as glucose, fructose, galactose, mannose, 2-keto-d-gluconic acid and rhamnose, malonic acid and inosine, cholesterol and arachidonic acid, glycosylation (immunoglobulin G [IgG] Fc-glycosylation), outer mitochondrial membrane 20 (TOMM20), monocarboxylate transporter 4 (MCT4), choline, choline derivatives, myo-/scyllo-inositol, lactate, fatty acids, several amino acids, cell membrane phospholipids, estrogen metabolites such as 16 alpha-OH E1/2-OH E1 and catechol estrogens (2-OH E1), and purine and pyrimidine metabolites, which were suggested as the TC oncometabolite.
|
30881111 |
2019 |
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 15 targeted studies and 16 untargeted studies revealed several potential metabolite signatures of TC such as glucose, fructose, galactose, mannose, 2-keto-d-gluconic acid and rhamnose, malonic acid and inosine, cholesterol and arachidonic acid, glycosylation (immunoglobulin G [IgG] Fc-glycosylation), outer mitochondrial membrane 20 (TOMM20), monocarboxylate transporter 4 (MCT4), choline, choline derivatives, myo-/scyllo-inositol, lactate, fatty acids, several amino acids, cell membrane phospholipids, estrogen metabolites such as 16 alpha-OH E1/2-OH E1 and catechol estrogens (2-OH E1), and purine and pyrimidine metabolites, which were suggested as the TC oncometabolite.
|
30881111 |
2019 |
Thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 15 targeted studies and 16 untargeted studies revealed several potential metabolite signatures of TC such as glucose, fructose, galactose, mannose, 2-keto-d-gluconic acid and rhamnose, malonic acid and inosine, cholesterol and arachidonic acid, glycosylation (immunoglobulin G [IgG] Fc-glycosylation), outer mitochondrial membrane 20 (TOMM20), monocarboxylate transporter 4 (MCT4), choline, choline derivatives, myo-/scyllo-inositol, lactate, fatty acids, several amino acids, cell membrane phospholipids, estrogen metabolites such as 16 alpha-OH E1/2-OH E1 and catechol estrogens (2-OH E1), and purine and pyrimidine metabolites, which were suggested as the TC oncometabolite.
|
30881111 |
2019 |